• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

Mixed Link Seen for Gestational Exposure to Flame-Retardant Chemicals and Childhood Obesity

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 12, 2024.

TUESDAY, Nov. 12, 2024 -- The association between gestational organophosphate ester (OPE) exposure and obesity in childhood is mixed, according to a study published in the November issue of Environment International.

Alicia K. Peterson, from Kaiser Permanente Northern California in Pleasanton, and colleagues analyzed OPEs in pregnancy urine samples of 5,087 individuals from 14 studies to examine whether OPE levels are associated with the risk for childhood obesity. Body mass index measurements were available for 3,827; 3,921; and 2,541 children in infancy (0.5 to 1.9 years), early childhood (2.0 to 4.9 years), and mid-childhood (5.0 to 10.0 years), respectively.

The researchers found that 16 to 21 percent of children across age groups had obesity. There was an association seen for the composite of dibutyl phosphate and di-isobutyl phosphate second and third versus first tertiles with an increased obesity risk in mid-childhood (relative risks [95 percent confidence intervals], 1.14 [1.02 to 1.28] and 1.11 [0.97 to 1.27], respectively); an inverse association was seen for bis (1,3-dichloro-2-propyl) phosphate second and third versus first tertiles with obesity risk (relative risks [95 percent confidence intervals], 0.85 [0.80 to 0.91] and 0.91 [0.77 to 1.07], respectively). For bis-(2-propylheptyl)-phthalate, bis(1-chloro-2-propyl) phosphate, bis(butoxyethyl) phosphate, and bis(2-chloroethyl) phosphate, there were no associations with obesity. In Bayesian kernel machine regression models, directions observed were consistent.

"Overall, our findings suggest a complex interplay between gestational OPE exposure and childhood obesity," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted November 2024

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.